AZ-话题@MedSci

#AZ#

260篇内容 | 4194人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1714812, encodeId=a2941e1481203, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Imbruvica和Gazyvo联用获FDA批准用于治疗慢性淋巴细胞白血病, objectType=article, longId=159146, objectId=e3eb15914659, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3eb15914659, replyNumber=0, likeNumber=70, createdTime=2019-04-01, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3eb15914659, moduleTitle=Imbruvica和Gazyvo联用获FDA批准用于治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3eb15914659)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714828, encodeId=6ca61e14828d5, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz J Med Biol Res：SKPin C1是一种有效抑制MM异常增殖和永生化的抑制剂, objectType=article, longId=165303, objectId=4c001653031e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c001653031e, replyNumber=0, likeNumber=57, createdTime=2019-12-07, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c001653031e, moduleTitle=Braz J Med Biol Res：SKPin C1是一种有效抑制MM异常增殖和永生化的抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c001653031e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714827, encodeId=12b31e14827ce, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Rhinology：MP-AzeFlu对过敏性鼻炎控制研究, objectType=article, longId=164817, objectId=fe2616481e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe2616481e72, replyNumber=0, likeNumber=66, createdTime=2019-04-25, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe2616481e72, moduleTitle=Rhinology：MP-AzeFlu对过敏性鼻炎控制研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe2616481e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714809, encodeId=cb911e1480928, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet：自体干细胞移植后Ixazomib的维持治疗, objectType=article, longId=155613, objectId=947f155613fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=947f155613fd, replyNumber=0, likeNumber=77, createdTime=2019-11-06, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=947f155613fd, moduleTitle=Lancet：自体干细胞移植后Ixazomib的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=947f155613fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714838, encodeId=f0791e14838bb, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz Dent J：氧化锆生物活性玻璃涂层可更好的达到上皮封闭的作用, objectType=article, longId=176519, objectId=ff101e6519d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff101e6519d2, replyNumber=0, likeNumber=58, createdTime=2019-10-23, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff101e6519d2, moduleTitle=Braz Dent J：氧化锆生物活性玻璃涂层可更好的达到上皮封闭的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff101e6519d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714803, encodeId=0d031e148039b, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz Oral Res：快速给予尼古丁和乙醇对牙齿移动的影响, objectType=article, longId=152879, objectId=b3cc1528e93b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3cc1528e93b, replyNumber=0, likeNumber=41, createdTime=2019-09-18, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3cc1528e93b, moduleTitle=Braz Oral Res：快速给予尼古丁和乙醇对牙齿移动的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3cc1528e93b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714832, encodeId=6ee81e14832bc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Iran Biomed J：新型聚腺苷二磷酸核糖聚合酶（RARP）抑制剂AZD2461能够下调VEGF表达和诱导前列腺癌细胞凋亡, objectType=article, longId=167119, objectId=81e116e11982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81e116e11982, replyNumber=0, likeNumber=84, createdTime=2019-09-08, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81e116e11982, moduleTitle=Iran Biomed J：新型聚腺苷二磷酸核糖聚合酶（RARP）抑制剂AZD2461能够下调VEGF表达和诱导前列腺癌细胞凋亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81e116e11982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714810, encodeId=b7131e1481069, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Stem Cell Res Ther：通过骨诱导的I型胶原沉积改善间充质干细胞/细胞外基质复合物的3D漂浮培养块中的YAP/TAZ活性, objectType=article, longId=157041, objectId=1dff15e041b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dff15e041b8, replyNumber=0, likeNumber=57, createdTime=2019-08-29, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dff15e041b8, moduleTitle=Stem Cell Res Ther：通过骨诱导的I型胶原沉积改善间充质干细胞/细胞外基质复合物的3D漂浮培养块中的YAP/TAZ活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dff15e041b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714797, encodeId=3ab21e1479776, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=FDA确证Nuplazid的安全性值得信赖, objectType=article, longId=149461, objectId=a79b14946143, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a79b14946143, replyNumber=0, likeNumber=84, createdTime=2019-04-29, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a79b14946143, moduleTitle=FDA确证Nuplazid的安全性值得信赖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a79b14946143)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714817, encodeId=6a921e14817eb, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz Oral Res：浓缩生长因子和脱细胞真皮基质的成骨作用的比较, objectType=article, longId=160200, objectId=b040160200df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b040160200df, replyNumber=0, likeNumber=52, createdTime=2019-07-02, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b040160200df, moduleTitle=Braz Oral Res：浓缩生长因子和脱细胞真皮基质的成骨作用的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b040160200df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714825, encodeId=95701e1482518, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Endod：鼻内3%丁卡因加0.05%羟甲唑啉(Kovanaze)对上颌磨牙的麻醉效果, objectType=article, longId=162572, objectId=303a1625e27e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=303a1625e27e, replyNumber=0, likeNumber=80, createdTime=2019-09-15, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=303a1625e27e, moduleTitle=J Endod：鼻内3%丁卡因加0.05%羟甲唑啉(Kovanaze)对上颌磨牙的麻醉效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=303a1625e27e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714807, encodeId=0c111e148077b, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Eltoprazine有望成为潜在的帕金森病新药, objectType=article, longId=154672, objectId=c1311546e212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1311546e212, replyNumber=0, likeNumber=57, createdTime=2019-03-22, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1311546e212, moduleTitle=Eltoprazine有望成为潜在的帕金森病新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1311546e212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714823, encodeId=85d51e148230f, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Acadia公司的帕金森精神病药物Nuplazid引起数百人死亡，美国司法部启动了营销调查, objectType=article, longId=162217, objectId=3ead16221e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ead16221e7b, replyNumber=0, likeNumber=69, createdTime=2020-01-02, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ead16221e7b, moduleTitle=Acadia公司的帕金森精神病药物Nuplazid引起数百人死亡，美国司法部启动了营销调查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ead16221e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714829, encodeId=e7e51e14829d7, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Gastroenterology：新型抑酸剂vonoprazan治疗特发性消化性溃疡, objectType=article, longId=165424, objectId=7574165424e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7574165424e0, replyNumber=0, likeNumber=78, createdTime=2020-01-25, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7574165424e0, moduleTitle=J Gastroenterology：新型抑酸剂vonoprazan治疗特发性消化性溃疡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7574165424e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714806, encodeId=c2f21e14806da, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Alembic制药宣布美国FDA已正式批准其不同剂量的Temazepam胶囊, objectType=article, longId=154606, objectId=d482154606ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d482154606ea, replyNumber=0, likeNumber=67, createdTime=2019-03-13, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d482154606ea, moduleTitle=Alembic制药宣布美国FDA已正式批准其不同剂量的Temazepam胶囊, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d482154606ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714791, encodeId=522f1e14791fb, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤, objectType=article, longId=145835, objectId=24c4145835bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24c4145835bc, replyNumber=0, likeNumber=74, createdTime=2018-12-04, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24c4145835bc, moduleTitle=EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24c4145835bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714830, encodeId=bb701e148300d, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=AZ和Forty Seven正在临床测试淋巴瘤的三重免疫疗法组合, objectType=article, longId=166027, objectId=c7dc16602e61, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7dc16602e61, replyNumber=0, likeNumber=73, createdTime=2020-01-31, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7dc16602e61, moduleTitle=AZ和Forty Seven正在临床测试淋巴瘤的三重免疫疗法组合, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7dc16602e61)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714837, encodeId=1be91e14837e5, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=并购复苏！渤健、uniQure、AZ等谁是大型药企下一个目标？, objectType=article, longId=174382, objectId=46321e438271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46321e438271, replyNumber=0, likeNumber=70, createdTime=2020-01-19, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46321e438271, moduleTitle=并购复苏！渤健、uniQure、AZ等谁是大型药企下一个目标？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46321e438271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714790, encodeId=2f0f1e1479005, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=辉瑞Trazimera（Herceptin生物仿制药）已获欧盟委员会的批准, objectType=article, longId=145635, objectId=848014563563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=848014563563, replyNumber=0, likeNumber=58, createdTime=2018-09-05, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=848014563563, moduleTitle=辉瑞Trazimera（Herceptin生物仿制药）已获欧盟委员会的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=848014563563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714819, encodeId=8ac41e14819ab, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=加拿大卫生部批准Otsuka/Lundbeck公司的REXULTI（brexpiprazole）用于重度抑郁症的辅助治疗, objectType=article, longId=160991, objectId=227616099155, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=227616099155, replyNumber=0, likeNumber=104, createdTime=2019-07-01, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=227616099155, moduleTitle=加拿大卫生部批准Otsuka/Lundbeck公司的REXULTI（brexpiprazole）用于重度抑郁症的辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=227616099155)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AZ

2020-05-29

仁心济世 (审核中...)

前往app查看评论内容

#AZ#

Imbruvica和Gazyvo联用获FDA批准用于治疗慢性淋巴细胞白血病

2019-04-01

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz J Med Biol Res：SKPin C1是一种有效抑制MM异常增殖和永生化的抑制剂

2019-12-07

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Rhinology：MP-AzeFlu对过敏性鼻炎控制研究

2019-04-25

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet：自体干细胞移植后Ixazomib的维持治疗

2019-11-06

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz Dent J：氧化锆生物活性玻璃涂层可更好的达到上皮封闭的作用

2019-10-23

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz Oral Res：快速给予尼古丁和乙醇对牙齿移动的影响

2019-09-18

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Iran Biomed J：新型聚腺苷二磷酸核糖聚合酶（RARP）抑制剂AZD2461能够下调VEGF表达和诱导前列腺癌细胞凋亡

2019-09-08

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Stem Cell Res Ther：通过骨诱导的I型胶原沉积改善间充质干细胞/细胞外基质复合物的3D漂浮培养块中的YAP/TAZ活性

2019-08-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

FDA确证Nuplazid的安全性值得信赖

2019-04-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz Oral Res：浓缩生长因子和脱细胞真皮基质的成骨作用的比较

2019-07-02

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

J Endod：鼻内3%丁卡因加0.05%羟甲唑啉(Kovanaze)对上颌磨牙的麻醉效果

2019-09-15

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Eltoprazine有望成为潜在的帕金森病新药

2019-03-22

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Acadia公司的帕金森精神病药物Nuplazid引起数百人死亡，美国司法部启动了营销调查

2020-01-02

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

J Gastroenterology：新型抑酸剂vonoprazan治疗特发性消化性溃疡

2020-01-25

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Alembic制药宣布美国FDA已正式批准其不同剂量的Temazepam胶囊

2019-03-13

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤

2018-12-04

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

AZ和Forty Seven正在临床测试淋巴瘤的三重免疫疗法组合

2020-01-31

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

并购复苏！渤健、uniQure、AZ等谁是大型药企下一个目标？

2020-01-19

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

辉瑞Trazimera（Herceptin生物仿制药）已获欧盟委员会的批准

2018-09-05

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

加拿大卫生部批准Otsuka/Lundbeck公司的REXULTI（brexpiprazole）用于重度抑郁症的辅助治疗

2019-07-01

科室
- - 订阅+
  - 更多科室
工具
服务